Cybin

Cybin is a clinical-stage biopharmaceutical company focused on developing psychedelic-based therapeutics for mental health conditions. The company's pipeline centers on deuterated compounds designed to enhance pharmacokinetic properties and therapeutic potential. CYB003, a deuterated psilocybin analog, targets major depressive disorder through modified molecular structure that aims to improve drug stability and duration of action. CYB004, a deuterated DMT molecule, addresses generalized anxiety disorder with similar pharmacological optimization. Deuteration involves replacing hydrogen atoms with deuterium isotopes to alter metabolic pathways and drug performance characteristics.

Headquartered in Toronto, Canada, Cybin operates research and development facilities across North America and Europe. The company conducts multi-phase clinical trials to establish safety profiles, dosing protocols and efficacy data required for regulatory approval. Clinical development follows established pharmaceutical pathways including investigational new drug applications and phased human trials. Founded in 2019, Cybin pursues therapeutic applications of psychedelic compounds through controlled clinical research rather than recreational contexts. The drug development methodology combines molecular engineering with psychiatric treatment protocols to create therapies for conditions with limited existing treatment options.